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Abstract
Aromatase inhibitors are currently included in the ‘optimal’
management of early-stage breast cancer. Uncertainty remains,
however, as to the most appropriate treatment strategy, particularly
for newly diagnosed women as they seek to trade off the cost,
toxicities and efficacy of the treatment options. Recent publications
provide conflicting advice on the role of aromatase inhibitors in the
treatment of postmenopausal patients with early-stage hormone
receptor-positive breast cancer. This review provides updates on
the clinical trials of aromatase inhibitors in early breast cancer and
tries to provide practical clinical guidance on their optimal use.
Introduction
Adjuvant hormonal therapy yields significant improvements in
disease-free survival (DFS) and overall survival (OS) in
women whose tumours express hormone receptors. Until
recently, the selective oestrogen receptor (ER) modulator
tamoxifen was regarded as the standard of care for women
with such disease, yielding reductions in risk of relapse of
39% and reduction in risk of death of 24% attributable to the
use of tamoxifen for about 5 years [1].
The superiority of the potent ‘third-generation’ aromatase
inhibitors (AIs) in advanced-stage breast cancer (BC)
underscored the need to test their efficacy in the adjuvant
setting in postmenopausal women with early-stage disease
[2-7]. In the past decade, several trials have been performed
to compare the efficacy and toxicity of the AIs with tamoxifen.
There are two types of trial: those that have randomly
assigned newly diagnosed women and those that have
randomly assigned women currently taking tamoxifen.
Of the trials involving newly diagnosed women, there are two
main trial structures:
￿ 5 years of an AI versus 5 years of tamoxifen
￿ A planned switch (that is, sequence) involving 2 years of
tamoxifen followed by 3 years of an AI versus 2 years of
an AI followed by 3 years of tamoxifen versus 5 years of
tamoxifen.
Of the trials involving women currently taking tamoxifen, there
are two main trial structures:
￿ An unplanned switch from tamoxifen to an AI following 2
to 3 years of tamoxifen versus 5 years of tamoxifen
￿ An unplanned switch after 5 years of tamoxifen to an AI or
placebo for a further 5 years.
The American Society of Clinical Oncology (ASCO) Tech-
nology Assessment of AIs states that optimal adjuvant
hormonal therapy for a postmenopausal woman with hormone
receptor-positive BC should include an AI [8]. The National
Institute for Health and Clinical Evidence (NICE) has also
recommended AIs, within their licensed indications, as
options for the adjuvant treatment of early-stage ER+ invasive
BC in postmenopausal women who are newly diagnosed and
those women currently on tamoxifen [9]. However, due to a
lack of results from directly comparative trials, neither guide-
line was able to recommend one particular treatment strategy
over another.
Uncertainty remains as to the most appropriate treatment
strategy, particularly for newly diagnosed women, as they
seek to trade off the cost, toxicities and efficacy of the
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treatment options. Recent publications provide conflicting
advice on the role of AI in the treatment of postmenopausal
patients with early-stage hormone receptor-positive BC. On
one hand, Chlebowski [10] recommends up-front AI for the
majority of patients, whereas Seruga and Tannock [11]
suggest that tamoxifen remains the endocrine treatment of
choice for most patients.
Newly diagnosed postmenopausal women with
hormone receptor-positive early breast cancer
Trials comparing 5 years of an aromatase inhibitor
versus 5 years of tamoxifen
The ATAC trial
The Arimidex, Tamoxifen, Alone or in Combination (ATAC)
study, involving 9,366 patients, was the first of these trials to
report and remains a ‘landmark’ trial in the treatment of early
BC. The initial report in The Lancet, with a median follow-up
of 33.3 months, demonstrated the superiority of anastrozole
compared with tamoxifen with 3-year DFS rates of 91.2% for
anastrozole versus 89.3% for tamoxifen in hormone receptor-
positive patients (hazard ratio [HR] 0.78, 95% confidence
interval [CI] of 0.65 to 0.93, P = 0.005) [12]. Results with the
combination were not significantly better than tamoxifen alone
(HR 1.02, 95% CI of 0.87 to 1.21, P = 0.8). The combination
arm has not been analysed subsequently, and it is unlikely
that other trials of combinations of AIs and tamoxifen will be
undertaken. In the latest update of this trial, with a median
follow-up of 100 months, anastrozole significantly increased
DFS in the hormone receptor-positive population by 74.2%
versus 70.1% for tamoxifen (HR 0.85, 95% CI 0.76 to 0.94,
P = 0.003) [13]. In anastrozole-treated patients, risk of recur-
rence was reduced by 24% (HR 0.76, 95% CI 0.67 to 0.87,
P = 0.0001) compared with tamoxifen. Risk of contralateral
BC was significantly reduced in the anastrozole arm by 40%
(HR 0.60, 95% CI 0.42 to 0.85, P = 0.004) compared with
tamoxifen. OS was similar with anastrozole and tamoxifen
(HR 0.97, 95% CI 0.86 to 1.11, P = 0.7).
The BIG 1-98 Collaborative Group study
This four-arm trial compared 5 years of tamoxifen versus 5 years
of letrozole, versus 2 years of tamoxifen plus 3 years of
letrozole, versus 2 years of letrozole and 3 years of tamoxifen.
This key study was designed to evaluate whether a planned
sequence of tamoxifen and letrozole (and vice versa) provides
benefits compared with 5 years of letrozole. A total of 8,010
women with hormone receptor-positive BC were randomly
assigned. In the head-to-head comparison of letrozole versus
tamoxifen for 5 years, at a median follow-up of 25.8 months,
351 events were noted in the letrozole arm and 428 with
tamoxifen, with estimated 5-year DFS rates of 84.0% for
letrozole and 81.4% for tamoxifen [14]. The risk of distant
recurrence was also significantly reduced (HR 0.73, 95% CI
of 0.60 to 0.88, P = 0.001).
More data from this trial were recently published [15]. This
involved 4,922 patients (only those patients who continued in
the monotherapy arms following the crossover of the trial)
with a median follow-up of 51 months. Three hundred fifty-
two events were recorded in the letrozole arm compared with
418 with tamoxifen, with estimated 5-year DFS rates of
84.0% versus 81.1% with tamoxifen (HR 0.82, 95% CI of
0.71 to 0.95, P = 0.007).
The results published in 2005 in favour of letrozole led to the
unblinding of the tamoxifen-alone arm, and 25.2% of the
patients selectively switched to letrozole for a median duration
of receiving letrozole of 18 months. As a result, the analysis
recently reported with 76 months of follow-up was divided as
either intention to treat (ITT) or by censoring patients who
switched. In this latest update [16], there is a statistically
significant difference in DFS (HR 0.88, 95% CI 0.78 to 0.99,
P = 0.03) for both ITT and censored populations and a trend
for OS benefit in the ITT population (HR 0.87, 95% CI 0.75 to
1.02,  P = 0.8) which reached significance in the censored
population (HR 0.81, 95% CI 0.69 to 0.94).
A meta-analysis of AIs versus tamoxifen in the adjuvant
setting was presented by Dr Ingle at the recent San Antonio
Breast Cancer Symposium [17]. The analysis was divided in
two cohorts. The first was a direct comparison of mono-
therapy strategies and included data from the ATAC and
Breast International Group (BIG) 1-98 trials. It included 9,856
patients with 50,000 woman-years of follow-up. At 5 years, AI
therapy was associated with an absolute 2.7% (standard error
[SE] 0.7%) decrease in BC recurrence (10.7% versus 13.4%,
relative decrease 20% [SE 5%], P = 0.00004). There
appeared to be greater proportional decreases in isolated
local recurrence (30% [SE 10%], P = 0.003) and in
contralateral disease (38% [SE 12%], P = 0.003) than in
distant recurrence (12% [SE 6%], P = 0.04). There was,
however, no significant improvement in BC mortality (5.5%
versus 6.5%, relative decrease 7% [SE 7%], P = 0.28).
Postmenopausal women with hormone
receptor-positive early breast cancer
currently receiving adjuvant tamoxifen
Sequencing endocrine treatments
The fundamental difference in the design of the following
trials is the time point of random assignment. The switch trials
randomly assign patients after 2 to 3 years of adjuvant endo-
crine treatment, whereas the sequencing trials randomly
assign patients from the start of treatment. As a conse-
quence, the former (switch) trial design selects a patient
population who have not already relapsed and may therefore
have a better prognosis and may potentially have tumours
that are more endocrine-responsive.
Switching trials
The IES trial
In the Intergroup Exemestane Study (IES) trial, 4,742 patients
who had received 2 to 3 years of tamoxifen were randomly
assigned to receive exemestane or continue tamoxifen to atotal of 5 years of hormonal therapy. After a median follow-up
of 30.6 months, the results favoured exemestane. Of a total of
449 events (local or metastatic recurrence, contralateral BC
or death), 183 were in the exemestane group and 266 in the
tamoxifen group [18]. The unadjusted HR in the exemestane
group was 0.68 (95% CI 0.56 to 0.82, P <0.001), represent-
ing a 32% reduction in risk and an absolute benefit in terms
of DFS of 4.7% compared with tamoxifen 3 years following
random assignment. DFS rates 3 years after random assign-
ment (following 2 to 3 years of tamoxifen treatment) were
91.5% in the exemestane group versus 86.8% in the tamoxifen
group. There was no significant difference in OS, with 93
deaths in the exemestane group and 106 in the tamoxifen
group. A more recent analysis was published, with a median
follow-up of 55.7 months [19]. There were 354 events in
patients switched to exemestane versus 455 in the tamoxifen
group (ITT population, HR 0.76, 95% CI 0.66 to 0.88,
P = 0.0001). In patients with hormone receptor-positive or
unknown disease, 339 events were noted in the exemestane
group compared with 438 in those continuing tamoxifen (HR
0.75, 95% CI 0.65 to 0.87, P = 0.0001). These latest IES
data estimated absolute differences in 5-year DFS of 3.4% in
the ITT population and 3.5% in the hormone receptor-positive
and unknown group compared with tamoxifen.
This analysis also showed an improvement in OS in the group
treated with exemestane versus tamoxifen. In the ITT
population, the result failed to reach conventional levels of
statistical significance, with 222 deaths versus 261 deaths in
the exemestane and tamoxifen arms, respectively (HR 0.85,
95% CI 0.71 to 1.02, P = 0.08). Considering the hormone
receptor-positive and unknown group, the difference was
barely statistically significant, with 210 deaths in the
exemestane arm versus 251 with tamoxifen (HR 0.83, 95%
CI 0.69 to 1.00, P = 0.05).
The ARNO 95 trial
Analysis of the Arimidex-Nolvadex (ARNO) 95 trial at a
median of 30.1 months, published in 2007, demonstrated
estimated DFS rates at 3 years of 93.5% for anastrozole
versus 89.3% for tamoxifen, with an absolute difference of
4.2% [20]. An OS benefit was seen in patients who switched
to anastrozole versus those who continued to receive
tamoxifen (HR 0.53, 95% CI 0.28 to 0.99, P = 0.045).
Meta-analysis of the ABCSG 8, the ARNO 95 and the ITA
trials
In the unplanned switching meta-analysis, including the
Austrian Breast & Colorectal Cancer Study Group (ABCSG)
8, ARNO 95 and Italian Tamoxifen Arimidex (ITA) trials,
involving 4,006 patients at a median follow-up of 30 months,
there were significantly fewer recurrences (92 events [4.6%]
versus 159 events [8.0%]) and significantly fewer deaths (66
[3.3%] versus 90 [4.5%]) in the group switched to
anastrozole versus those remaining on tamoxifen [21]. A 29%
reduction in risk of death in the anastrozole arm (HR 0.71,
95% CI of 0.52 to 0.98, P = 0.04) versus the tamoxifen arm
was seen. The anastrozole arm also demonstrated a 45%
improvement in event-free survival (HR 0.55, 95% CI of 0.42
to 0.71, P <0.0001) and a 39% improvement in distant
recurrence-free survival (HR 0.61, 95% CI of 0.45 to 0.83,
P = 0.0015).
Sequencing trials
The ABSCG Trial 8
The ABSCG Trial 8 explored the tamoxifen-AI sequencing
strategy in postmenopausal women with hormone-responsive
early BC. The ABSCG Trial 8 compared 5 years of tamoxifen
versus 2 years of tamoxifen followed by 3 years of anastrozole
[22]. A recent update of this trial at a median of 72 months of
follow-up showed that sequencing tamoxifen to anastrozole
significantly improved relapse-free survival (RFS) in the ITT
population by 21% (HR 0.79, 95% CI 0.65 to 0.95,
P = 0.038). Patients treated with sequential endocrine
treatment showed significantly improved OS, with a 23%
reduction in the number of deaths (HR 0.77, 95% CI 0.61 to
0.97, P = 0.025).
The BIG 1-98 trial
Results of the sequencing arms of the trial as described
previously were recently presented [15], with a median
follow-up of 71 months. Two pairwise comparisons were
presented: letrozole versus sequencing 2 years of letrozole
followed by 3 years of tamoxifen (Let x2 → Tam x3) or
sequencing 2 years of tamoxifen followed by 3 years of
letrozole (Tam x2 → Let x3). Although no statistically signifi-
cant differences in DFS were demonstrated (5-year DFS
rates of 87.9% for Let, 87.6% for Let x2 → Tam x3 and
86.2% for Tam x2 → Let x3), subset analysis revealed an
increased risk of recurrence in the first 2 years of treatment in
the Tam x2 → Let x3 group, especially for the node-positive
population. There was no apparent benefit of the letrozole-
alone versus the [Let x2 → Tam x3] strategy at this stage of
follow-up.
The TEAM trial
The Tamoxifen Exemestane Adjuvant Multinational (TEAM)
trial was originally designed as a monotherapy comparison of
5 years of examestane versus tamoxifen. However, the results
of the IES trial led to the amendment of the protocol and all
patients on tamoxifen switched to examestane. The median
time patients on the tamoxifen arm took tamoxifen was
2.75 years. At a median of 2.75 years of follow-up [23], the
trial failed to reach its primary endpoint, DFS (HR 0.89, 95%
CI 0.77 to 1.03, P = 0.12), but was associated with improve-
ments in RFS (HR 0.85, 95% CI 0.72 to 1.00, P = 0.05) and
time to distant metastases (HR 0.81, 95% CI 0.67 to 0.98,
P <0.03).
Meta-analysis of the switch strategy
A meta-analysis reviewed the switch strategy [17] using data
from the GABG (German Adjuvant Breast Study Group)/
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included 9,015 patients with 33,000 woman-years of follow-
up. At 6 years from treatment divergence (that is, 8 to 9 years
from allocation to endocrine treatment), AI therapy was
associated with an absolute 3.5% (SE 1.1%) decrease in BC
recurrence (12.6% versus 16.1%, relative decrease 29% [SE
6%],  P <0.00001). There appeared to be greater propor-
tional reductions in isolated local recurrence (40% [SE 13%],
P = 0.002) and in contralateral disease (35% [SE 16%],
P= 0.03) than in distant recurrence (24% [SE 7%], P= 0.001).
AIs yielded an absolute 1.6% (SE 0.8%) decrease in BC
mortality (6.3% versus 8.0%, relative decrease 22% [SE
9%], P = 0.02). The benefit was irrespective of progesterone
receptor (PR) status, age, grade and lymph node status.
Furthermore, there was no evidence of increase in overall
mortality or non-BC deaths with the use of the AI, causing no
concern about safety issues.
Trial comparing 5 years of ‘extended’ treatment with an
aromatase inhibitor versus 5 years of placebo following
5 years of adjuvant treatment with tamoxifen
The MA-17 trial
Due to the early termination of the National Cancer Institute of
Canada MA-17 (MA-17) trial, its aims will never be answered.
The trial involved 5,187 patients who had already received
tamoxifen for 5 years and then were randomly assigned to a
further 5 years’ therapy with either letrozole or placebo. At a
median follow-up of 2.4 years, the independent data and
safety monitoring committee recommended termination of the
trial as a significant difference in favour of letrozole was seen.
The estimated 4-year DFS rates were 93% and 87% for
letrozole and placebo, respectively (P <0.001) [24]. More
recent analysis of the MA-17 trial now indicates a survival
benefit for extended adjuvant therapy with letrozole in lymph
node-positive patients (HR 0.61, P = 0.04) [25].
In the MA-17 trial, patients were randomly assigned within
3 months of stopping tamoxifen. The effect of ‘delayed’
extended adjuvant therapy with letrozole has been evaluated
in those women who, after unblinding of the trial, opted for an
unplanned switch from placebo to letrozole. Compared with
the hormone receptor-positive women who chose not to do
so and despite having worse prognostic features, those who
switched had significantly improved DFS (HR 0.31, 95% CI
0.18 to 0.55, P <0.0001) [26].
Comparison of toxicity of AIs versus
tamoxifen in newly diagnosed patients and
those patients currently taking tamoxifen
switched to an AI
Venous thromboembolic events
Trials of AIs versus tamoxifen show a lower risk of venous
thromboembolic events (VTEs) with AIs. The exact mecha-
nism that potentiates thrombotic events is unclear but
possibly involves, among other mechanisms, tamoxifen-
induced decrease in antithrombin III and protein C levels
[27,28]. Previous trials of tamoxifen versus placebo have
shown a significant increase in the risk of VTEs, which may be
related to its partial agonist oestrogenic actions. In the National
Surgical Adjuvant Breast and Bowel Project (NSABP) P1 trial,
the risk ratios for stroke (1.59), pulmonary embolism (3.01) and
deep vein thrombosis (DVT) (1.60) were all raised with
tamoxifen treatment compared with placebo [29].
After 68 months of follow-up in the ATAC trial, the incidence
of any thromboembolic event was lower with anastrozole
compared with tamoxifen (2.1% versus 3.5%, P = 0.0006)
and also for VTEs (3% versus 5%, P = 0.0004) [30].
Similarly, in the BIG 1-98 trial, letrozole was associated with
fewer thromboembolic events compared with tamoxifen
(1.5% versus 3.5%, P <0.001). The switching trials have also
shown a reduction in VTEs: The IES trial showed incidences
of VTEs of 1.0% for exemestane and 1.9% for tamoxifen
(P = 0.003). The combined analysis of ABCSG 8 and ARNO
95 showed 21 VTEs with tamoxifen and only 5 with
anastrozole [31]. In the MA-17 trial, VTEs were rare and not
significantly different from the placebo. From the above, it is
clear that patients with a previous VTE should receive an AI
rather than tamoxifen, irrespectively of recurrence risk.
Gynaecological side effects
The oestrogen agonist activity of tamoxifen on endometrium
can be associated with vaginal bleeding and discharge,
menstrual irregularities and endometrial changes (hyper-
plasia, polyps, endometriosis and uterine fibroids), and an
increased incidence of endometrial cancer is recognised. In
the NSABP P1 prevention study, there was a 2.5-fold increase
in endometrial cancer with tamoxifen treatment [29]. Most
studies involving AIs in the adjuvant setting report a reduced
incidence of vaginal bleeding, with a reduced need for
interventions such as hysterectomy (5.1% versus 1.3%) in
the 68-month follow-up ATAC data [12] and endometrial
biopsy (7.2% versus 1.9%) being reported in the 25.8-month
follow-up BIG 1-98 data [14]. Given the absence of agonist
activity of the AIs, the incidence of vaginal discharge is
usually reported as being less with this class of agents. In the
two available AI quality-of-life studies carried out, decreased
libido, vaginal dryness and dyspareunia were reported more
frequently with anastrozole and exemestane than tamoxifen
[32,33].
Hot flashes, either de novo or exacerbation of pre-existing
symptoms, are a recognised feature of endocrine therapies,
reported in up to 46% of patients [34]. They are attributed to
the sudden decrease in circulating oestrogen levels, and due
to their abrupt onset, they are more bothersome than the
symptoms developed during natural menopause. Hot flashes
are reported with slightly less frequency in the two studies in
newly diagnosed women: 36% for anastrozole versus 41%
for tamoxifen after 68 months of follow-up [12] and 34% for
letrozole versus 38% for tamoxifen after 25.8 months of
follow-up [14]. In studies exploring unplanned switching
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similar to that of other studies [18,31]. Unsurprisingly, in the
MA-17 study of extended adjuvant therapy, use of letrozole
led to a higher frequency of hot flashes compared with
placebo (47% versus 41%, respectively) [24]. Interestingly, in
one study, women who reported hot flashes at baseline were
less likely to develop recurrent BC than those who did not
report hot flashes (12.9% versus 21%, P = 0.01) [35].
Bone mineral density
Trials of AIs versus tamoxifen in postmenopausal women have
shown an increased risk of fractures with the use of all AIs
[12,14,18]. Comparisons between AIs and tamoxifen are
complicated by the fact that the effect of tamoxifen on bone
mineral density (BMD) is not neutral but agonistic [36].
Previous trials of tamoxifen compared with placebo in
postmenopausal women have shown an increase in BMD
from tamoxifen use and a 19% reduction (nonsignificant) in
the incidence of fractures [29].
In the ATAC trial at 68 months, the incidences of fractures
were 11% with anastrozole versus 7.7% with tamoxifen. The
5-year bone subprotocol of the ATAC trial showed that the
loss of BMD from baseline was an average of 6.1% in the
lumbar spine and 7.2% in the hip with anastrozole compared
with a 2.8% gain in the lumbar spine and 0.7% gain in the hip
with tamoxifen (P <0.0001) [37]. However, no patient with
normal bone at baseline became osteoporotic after 5 years of
treatment; to develop osteoporosis, a woman would need to
lose 15% to 20% of normal peak bone mass. In the BIG 1-98
study, fractures were significantly more frequent in the
letrozole group than in the tamoxifen group at 25.8 months
(5.7% versus 4%, P <0.001) [13].
In the IES trial at 55.7 months of follow-up, rates of osteo-
porosis (of any grade) were 7.0% with exemestane and 4.9%
with tamoxifen (P = 0.003) [18]. In the MA-17 trial at
2.4 years, rates of osteoporosis (of any grade) were 5.8%
with letrozole and 4.5% with placebo (P = 0.07) [24].
Although claims of superiority have been made for particular
AIs with respect to bone loss [38], the LEAP (Letrozole,
Exemestane, and Anastrozole Pharmacodynamics) trial involv-
ing 90 patients at 24 weeks of treatment showed that the
steroidal and nonsteroidal AIs appear to have similar effects
on bone biochemical measurements and presumably bone
turnover. All three licensed AIs result in increases in bone
turnover. With the exception of parathyroid hormone (PTH), in
which there is a greater decrease in PTH with exemestane
than with anastrozole (P = 0.04), there were no statistically
significant differences between the AIs [39].
At present, it is not clear to what extent the difference in bone
density seen between AIs and tamoxifen is due to their direct
effect on bone or to the absence of the bone preservation
effect of tamoxifen. It is reassuring that the relative incidence
of fractures with anastrozole has not increased over time in
the ATAC trial and appears to stabilise after 2 years
[12,30,40,41]. Recent trials have provided evidence that
osteopenia/osteoporosis, either present at the start of
therapy with AIs or developing during treatment, can be
prevented with the use of bisphosphonates [42-44].
Guidance on the management of bone loss induced by the
use of AIs has recently been published (Figure 1).
Arthralgia
AIs have been associated with a broad range of musculo-
skeletal adverse events (in addition to the effects on bone
health described in the preceding paragraph) that have been
loosely categorised under the term of AI-related arthralgias. In
the trials of adjuvant AI therapy such as ATAC, IES, BIG 1-98
and MA-17, bone and joint symptoms were categorised in a
variety of ways, and estimates for the incidence of musculo-
skeletal problems in these trials range from 5% to 36% [45].
However, this may be an underestimate in view of the incon-
sistency of reporting these symptoms. Crew and colleagues
[46] reported a cross-sectional survey of 200 consecutive
women receiving adjuvant AI therapy, with a higher
prevalence of these symptoms. Ninety-four (47%) reported
having AI-related joint pains, and 88 (44%) reported joint
stiffness. Patients who had received taxanes were four times
more likely to report symptoms. The pathophysiology of AI-
related arthralgias is not well understood, but it is thought to
be related to oestrogen deprivation. Magnetic resonance
imaging (MRI) studies have suggested that tenosynovial
changes are seen on MRI with AIs but not with tamoxifen, and
these correlate with a significant decrease in hand grip
strength [47].
Cardiac side effects
The cardiovascular consequences of tamoxifen remain the
subject of much debate. Tamoxifen has been shown to
reduce lipid levels [48], coronary plaques and C-reactive
protein and modulate nitric oxide production [49]. However,
the clinical consequences of these changes are uncertain
and trials of tamoxifen versus placebo in the preventive
setting have not indicated differences in cardiac events [50].
At 28 months of follow-up, the BIG 1-98 trial reported a
significant excess of cardiac (2.1% versus 1.1%, P = 0.0003)
grade 3 to 5 events for the letrozole-containing arm [51].
However, at a median follow-up of 51 months, no significant
differences in cardiovascular events in the two arms of the
study were seen [15].
In the ATAC trial, no statistically significant differences in
cardiac events were reported. Ischaemic cardiovascular
disease occurred in 4.1% of patients receiving anastrozole
versus 3.4% in the tamoxifen arm, and deaths due to
ischaemic heart disease occurred in 49 and 46 patients,
respectively. The ABCSG 8, ARNO 95 and ITA trials have
not reported an excess of cardiovascular disease or
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tamoxifen [52].
In the most recent update of the IES trial [19], deaths from
cardiac events were similar in exemestane and tamoxifen
groups (22.1% versus 20.9%, P = 0.34). Additionally, there
were no statistically significant differences in MIs (1.3 versus
0.8,  P = 0.08), angina (7.1% versus 6.5%, P = 0.44) or
cerebrovascular accidents (2.5% versus 2.4%, P = 0.89)
observed. In the extended adjuvant setting, letrozole was not
associated with more cardiovascular events than placebo at a
median follow-up of 2.4 years [24].
At present, it is not clear whether the early concerns with
cardiac morbidity in the BIG 1-98 trial are specific to letrozole
or are a class effect of AIs. Inconsistency in cardiac event
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Figure 1
Guidelines on the management of postmenopausal women treated with aromatase inhibitors. AST, aspartate aminotransferase; BMD, bone mineral
density; BMI, body mass index; DXA, dual-energy x-ray absorptiometry; ESR, erythrocyte sedimentation rate; FBC, full blood count; GT, glutamine
transpeptidase. Adapted with permission from [81].reporting in the major AI trials makes cross-trial interpretation
difficult. Further follow-up of existing trials is needed, and
head-to-head trials of AIs will help to answer these important
questions. Current data suggest that AIs are not associated
with an excess risk of cardiovascular events.
Quality-of-life evaluations
The first published results from a longitudinal follow-up of the
impact of 5 years of adjuvant AI therapy on health-related
quality of life (HRQoL) involved anastrozole and showed that
the efficacy and tolerability benefits of anastrozole compared
with tamoxifen over the full 5-year recommended adjuvant
treatment period are not at the expense of HRQoL [53]. The
switch from tamoxifen to exemestane did not influence
endocrine symptoms present after 2 to 3 years of tamoxifen,
nor did the switch lead to significant reports of new
symptoms. Results indicate that the clinical benefits of
exemestane over tamoxifen are achieved without significant
detrimental effect on quality of life [33]. Data from the MA-17
trial indicate no overall adverse effect of letrozole in quality of
life but small, though significant, worse outcomes in body
pain and vasomotor symptoms [54].
Discussion
Three different third-generation AIs have been compared with
tamoxifen (and in the case of letrozole versus placebo in the
extended adjuvant setting) in the context of early-stage BC
(Table 1). The largest studies have examined the AIs initiated
at different disease time points with different patient
populations involving different reporting methodologies with
respect to efficacy and toxicity. Direct comparison of these AI
trials is thereby problematic.
While follow-up of these studies is relatively short compared
with the wealth of data on tamoxifen, the studies demonstrate
that AIs significantly improve DFS, event-free survival and
distant recurrence compared with tamoxifen. More recent
data now show an OS benefit in patients switched to
anastrozole and exemestane compared with continuation of
tamoxifen [18,20,21]. Also, OS has been shown to improve
in node-positive patients treated with letrozole in the
extended adjuvant trial after 5 years of tamoxifen versus
placebo [25].
In speculating what the longer-term benefits of AIs might be,
it is important to recognise that a carryover effect of adjuvant
therapies is well recognised with differences in RFS and OS
increasing beyond the treatment period. For example, the
difference in mortality attributable to tamoxifen at 5 years was
only 3.6% compared with 9.2% at 15 years, and this for a
comparison of active treatment versus none [1]. Similarly, it is
interesting to consider an early Swedish trial comparing use
of tamoxifen for 2 years versus 5 years [55]. No benefits of
the more prolonged treatment were noted before 5 years
following random assignment. With the benefit of more
prolonged follow-up and the Oxford overviews, 5 years of
tamoxifen has, until recently at least, been regarded as the
standard of care in early-stage BC. In adjuvant endocrine
therapy, prolonged follow-up to truly evaluate long-term
benefits is clearly required.
AIs have also demonstrated significant improvements in
tolerability compared with tamoxifen. Whilst these benefits
should be balanced with the increased risk of fracture and
arthralgia posed by AIs, patients considered to be low risk in
terms of recurrence could benefit from the altered toxicity
profile of AIs compared with tamoxifen. Overall, efficacy
benefits have been established without an apparent detri-
mental effect on quality of life in the anastrozole and
exemestane studies [32,33].
Available online http://breast-cancer-research.com/content/11/5/211
Page 7 of 12
(page number not for citation purposes)
Table 1
Efficacy results of major aromatase inhibitor trials
DFS DFS  OS  OS 
Trial AI versus tamoxifen Strategy Follow-up, months  HR P value HR P value
ATAC Anastrozole Up-front 100 0.85 0.003 0.97 0.7
BIG Letrozole Up-front 76 0.88 0.03 0.87 0.8
BIG Letrozole-Tamoxifen Sequencing 71 0.96 NS NS
BIG Tamoxifen-Letrozole Sequencing 71 1.05 NS NS
TEAM Examestane Up-front 33 0.89 0.12 NS
IES Examestane Sequencing 55.7 0.76 0.0001 NS
ARNO Anastrozole Sequencing 30 0.66 0.049 0.53 0.045
MA-17 Letrozole Extended 30 0.58 0.001 NS
ABCSG 6a Anastrozole Extended 62 0.62 0.031 NS
ABCSG, Austrian Breast & Colorectal Cancer Study Group; AI, aromatase inhibitor; ARNO, Arimidex-Nolvadex; ATAC, Arimidex, Tamoxifen, Alone
or in Combination; BIG, Breast International Group; DFS, disease-free survival; HR, hazard ratio; IES, Intergroup Exemestane Study; NS, not
significant; OS, overall survival; TEAM, Tamoxifen Exemestane Adjuvant Multinational.The ASCO guidelines and the NICE technology appraisal on
the use of AIs concur that optimal adjuvant hormonal therapy
for a postmenopausal woman with receptor-positive BC
includes an AI, either as initial therapy or after treatment with
tamoxifen [8,9]. However, the practical questions remain:
when to initiate an AI and in which patients.
Tamoxifen metabolism
Tamoxifen has relatively low affinity for its target, the ER, but
its metabolites 4-OH-tamoxifen and endoxifen (N-desmethyl-
4-hydroxytamoxifen) are 10 to 100 times more potent. In the
liver, tamoxifen is converted to N-desmethyl-tamoxifen by
CYP3A4/5 and subsequently to endoxifen by CYP2D6. An
alternate route of endoxifen production is mediated by
CYP2D6, converting tamoxifen to 4-hydroxy-tamoxifen, which
is further metabolized to endoxifen via CYP3A4/5. Serum
levels of endoxifen are 5 to 10 times higher than that of 4-
OH-tamoxifen and 100 times more than that of tamoxifen, and
therefore endoxifen is considered the main active metabolite
[56-58]. The enzyme CYP2D6 (as well as CYP3A4/5) is a
member of the cytochrome P450 system and is involved in
the oxidation of a wide range of substrates. Besides being
involved in tamoxifen metabolism, it metabolizes codeine to
morphine. About 7% of Caucasians carry null alleles, which
are homozygous polymorphisms that encode for an inactive
allele [59].
Interest in tamoxifen metabolites started with a report by Goetz
and colleagues [60] which correlated response to tamoxifen
with CYP2D6 polymorphisms. Until now, the evidence has
been mixed, with the majority of the studies suggesting that
patients with defective tamoxifen metabolism (as a conse-
quence of either genetic polymorphisms or the concomitant
use of drugs that inhibit CYP2D6) have an inferior clinical
outcome. However, there are also clinical studies indicating
the opposite, or no detrimental effect [61]. Another two
clinical studies presented in ASCO 2009 reported
contradictory results [62,63]. In 2006, the US Food and Drug
Administration issued a label warning in the tamoxifen
package, and several companies now offer genotyping tests
to assess CYP2D6 status. At present, one cannot draw
definite conclusions regarding the appropriateness of full-
scale genotype testing, although most practitioners would
avoid the concomitant use of strong pharmacologic inhibitors
of CYP2D6 with tamoxifen and some may even provocatively
consider that the small increase in efficacy with the modern
AIs over tamoxifen would be lost [64] if poor metabolizers
were excluded from the clinical trials.
Biomarkers to guide the use of adjuvant
endocrine therapy
Patients with hormone-responsive disease represent a
spectrum with differing degrees of clinical benefit derived
from adjuvant endocrine treatments. The level of expression
of ERs correlates with the degree of response to endocrine
therapies [65] but does not differ between tamoxifen and AIs.
Similarly for PRs [66], the benefit correlates with the level of
expression. Initially, it was suggested that ER+ PR– tumours
gain even more benefit with anastrozole compared with
tamoxifen than the rest of the hormone-responsive tumours
[67]; however, subsequent studies failed to confirm this [66].
Preclinical studies have suggested that overexpression of
human epidermal growth factor receptor 2 (HER2) in hormone
receptor-positive tumours is associated with endogenous
resistance to tamoxifen [68]. Retrospective clinical data
indicate that HER2 overexpression in advanced BC is
associated with relative resistance to treatment with
tamoxifen [69] and greater benefits from the use of an AI
[70]. Similar results have been shown in the neoadjuvant
setting [71], but not in the adjuvant setting [66,72]. Finally,
the presence of high levels of Ki-67 indicates aggressive
disease and can be used as a predictive marker for choosing
an AI over tamoxifen in the adjuvant setting [73], with
significant benefits in DFS (HR [Let:Tam] 0.53, 95% CI 0.39
to 0.72). Current data indicate that biomarkers may define a
group with some resistance to endocrine therapy but do not
justify the use of these biomarkers in routine clinical practice
in selecting treatment with AIs over tamoxifen.
Newly diagnosed patients
For newly diagnosed patients, those at high risk of early
recurrence (including patients with nodal involvement and/or
high-grade tumours, PR+ tumours or HER2+ tumours) are more
likely to benefit from the introduction of an AI up front. Some
patients considered to be low risk in terms of recurrence may
also be considered for an up-front AI on the basis of the
improved tolerability that AIs offer versus tamoxifen.
Initial reports from the ATAC trial generated the hypothesis of
an increased benefit in the PR– tumours [67], but subsequent
reports refuted this hypothesis [66]. To date, there are no
data to support elective use of an AI in a particular endocrine-
responsive subset. High expression of HER2 has been
suggested to confer resistance to tamoxifen [74], and there
are data from the neoadjuvant setting that letrozole is more
effective than tamoxifen in women with HER2+ tumours [75].
However, there are no robust data from the major adjuvant
trials to establish this practice. Despite this, women
overexpressing HER2 are at higher risk of early relapse and
could be candidates for an AI on this basis. Prospectively
sequencing newly diagnosed patients to 2 years of tamoxifen,
followed by 3 years of an AI, may be appealing with respect
to toxicity, with adverse effects of each agent lessened with
reduced exposure.
Patients currently on tamoxifen
For these patients, the unplanned switch approach appears
appealing if reduction in risk of relapse is considered, and
compared with ‘up-front’ comparisons, this approach appears
to be associated with a survival benefit. Patients randomly
assigned in these switching studies, however, were those
who had not recurred already and probably represent a more
Breast Cancer Research    Vol 11 No 5 Kesisis et al.
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received 2 to 3 years of tamoxifen, completion of 5 years of
endocrine therapy that includes an AI should be considered.
While the optimal duration of endocrine therapy was
generally regarded as being about 5 years, the results of the
extended adjuvant therapy trial (MA-17) challenge this view.
Patients with node-positive disease who have received
5 years of tamoxifen benefit from the introduction of an AI
[24]. The optimal duration remains unclear following the early
discontinuation of the study as mandated by the trial design.
Recent follow-up data of the MA-17 trial suggest that
benefits of an AI are seen versus placebo in patients even
following its late introduction [26].
The results of trials of extended tamoxifen have been incon-
sistent. Reports from earlier trials [76,77] indicated that no
additional advantage was obtained with extended tamoxifen
therapy and actually reported a trend toward inferior survival.
Only a smaller trial [78] suggested a possible benefit from
increasing the length of adjuvant tamoxifen treatment. Two
newer trials are trying the resolve the discrepancy. In the first,
ATLAS (adjuvant tamoxifen, longer against shorter), the
longer duration of tamoxifen therapy was associated with a
12% relative reduction in the risk for BC recurrence com-
pared with 5 years of treatment alone (HR = 0.88, P = 0.05)
[79]. In the aTTom (adjuvant Tamoxifen–To offer more?) trial,
which again compared 5 versus 10 years of adjuvant tamoxi-
fen, there was a nonstatistically significant trend in favour of
the longer treatment [80]. Apart from a doubling of the
incidence of endometrial tumours, there were no major safety
issues raised. In terms of which AI to use, until head-to-head
AI trial data comparing efficacy and tolerability are provided,
AIs should be prescribed within their licensed indications as
outlined below (Table 2).
Is there a role for tamoxifen alone?
For women at low risk of relapse (ER+, PR+, grade I/II, node-
negative), the benefit of AIs in terms of DFS is likely to be
small. None of the trials has reported the benefit for low-risk
patients in absolute terms. Given the wealth of data in terms
of long-term toxicity with tamoxifen, its use may be con-
sidered appropriate for such patients. However, even for
these patients, AIs may be appropriate if patients have
contraindications for tamoxifen (for example, DVT/pulmonary
embolism) or may be intolerant to the side effects of
tamoxifen (for example, hot flashes and night sweats).
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